Amag endures an FDA rejection; Advaxis teams up with Biocon on cancer drug;

@FierceBiotech: The dethroned 'King of Biotech' will stay exiled in prison. News | Follow @FierceBiotech

@JohnCFierce: The 4th quarter was big--Q4 venture haul pushes 2013 biotech investing past $4.5B--and the year was fine, overall. Story | Follow @JohnCFierce

@DamianFierce: Your chance to vote: Who are the most influential people in biopharma today? Survey | Follow @DamianFierce

@EmilyMFierce: ICYMI, yesterday's edition of FierceBiotech Research featured Alzheimer's research and new nanotech. Read | Follow @EmilyMFierce

> The FDA rejected Amag Pharmaceuticals' ($AMAG) effort to widen the label for Feraheme, its drug to treat iron deficiency anemia. More

> Advaxis ($ADXS) has teamed up with India's Biocon to co-develop ADXS-HPV, an immunotherapy for HPV-associated cervical cancer, in India and other emerging markets. News

> EnVivo Pharmaceuticals has kicked off a Phase III trial of EVP-6124, an alpha-7 potentiator designed to treat Alzheimer's disease. Release

Medical Device News

@FierceMedDev: Special Report: 2013's top FDA approvals in med tech. Report | Follow @FierceMedDev

@MarkHFierce: Check out the latest issue of FierceDiagnostics, now with expanded biomarker coverage. Issue | Follow @MarkHFierce

@MichaelGFierce: NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Covidien gets FDA OK for LigaSure laparoscopic surgical device. News | Follow @EmilyWFierce

> Diagnostics buoyed Abbott's Q4 numbers, but diabetes sales declined. Report

> Cohera Medical's surgical sealants attracted a $26.3M Series D. More

> St. Jude Medical reports solid growth, predicts more to come. News

Pharma News

@FiercePharma: What's a $2.9B deal + increasing sales equal? One enthused new CEO at Forest. Yesterday's story | Follow @FiercePharma

@TracyStaton: Here's my story on yesterday's Swiss job shuffle. Story | Follow @TracyStaton

@EricPFierce: Who do you think are the most influential people in biopharma? Like to see someone from manufacturing. Survey | Follow @EricPFierce

@CarlyHFierce: Vivus has lost more than half its board, its CFO, 2 CEOs and 20 staffers--and now its commercial chief, apparently. More | Follow @CarlyHFierce

> Now it's New York: Novartis eyes another 500-plus job cuts with plant shutdown. News

> Appeals court gives GSK another shot at AbbVie in HIV drug-pricing fight. Story

> Sanofi's MS pill Aubagio wins final thumbs-up from U.K. cost-effectiveness watchdogs. More

> Par Pharma nabs injectables specialist JHP for $490M in private-equity auction. Report

Drug Delivery News

> Nano-scaffold delivers genetic treatment to spur blood vessel growth. News

> Biotronik launches drug-releasing balloon Passeo-18 Lux in Europe. Article

> NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story

> Rooted delivery vehicles use electric charge and gravity to release drugs over time. Piece

> Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story

> Novartis launches joint pain gel in India with Phosphagenics' delivery tech. Item

Diagnostics News

> Researchers from Singapore and China find a new esophageal cancer biomarker. More

> A finger-prick blood test could uncover sports concussions on the field. Article

> Myriad Genetics will market a breast cancer Dx made by a Siemens spinoff. Story

> FDA approves Affymetrix's blood test for developmental disabilities. Coverage

> Illumina brings next-generation sequencing to Amgen companion Dx deal. News

> LabCorp CEO promises continued rollout of new genomics-based Dx tests. Item